HER2 protein overexpression is a condition where cells produce an excessive amount of a specific protein that can drive aggressive cancer growth, but modern medicine has developed targeted treatments that have dramatically changed outcomes for people diagnosed with this type of cancer.

Understanding HER2 and Its Role in the Body

The HER2 gene, also known as human epidermal growth factor receptor 2 or ERBB2, is a normal part of human biology. This gene provides instructions for making HER2 proteins, which sit on the surface of cells throughout the body. In healthy cells, these proteins act as receptors that help control how cells grow, divide, and repair themselves when needed.^[1]

HER2 belongs to a family of four related receptors called the epidermal growth factor receptor family. All four members of this family share a similar structure: they have a part that extends outside the cell to receive signals, a section that crosses through the cell membrane, and an inner portion with tyrosine kinase activity, which is a type of enzyme that helps transmit growth signals inside the cell.^[2]

The HER2 receptor is a large protein made up of 1,255 amino acids and weighing 185 kilodaltons. The gene that codes for it is located on the long arm of human chromosome 17. Under normal circumstances, cells have exactly two copies of the HER2 gene, and the proteins produced from these genes help maintain orderly cell growth and survival.^[2]

What Happens When HER2 Becomes Overexpressed

Sometimes the HER2 gene stops working correctly and begins making too many copies of itself, a process called gene amplification. When a cell has extra copies of the HER2 gene, it produces far more HER2 proteins than normal. This condition is called HER2 protein overexpression, and it fundamentally changes how cells behave.^[1]

When too many HER2 receptors crowd the cell surface, they begin to pair up with each other without needing the usual trigger signals from outside the cell. These paired receptors activate powerful growth pathways inside the cell, particularly the MAPK/ERK and PI3K/AKT/mTOR signaling pathways. These pathways normally regulate cell growth and survival, but when overactivated, they tell cells to grow and divide in an uncontrolled way.^[9]

The overexpression causes cells to ignore normal growth controls and multiply rapidly. This uncontrolled growth can transform normal cells into cancer cells or make existing cancer cells grow much more aggressively. The genes that can cause this kind of transformation are called oncogenes, and HER2 is one of the most important oncogenes in human cancer.^[5]

Epidemiology and Prevalence

HER2 protein overexpression occurs in approximately 15 to 30 percent of breast cancers, making it one of the most common molecular abnormalities in this disease. Research teams led by scientists in the 1980s first established this connection and showed that HER2 could cause normal cells to grow uncontrollably like cancer cells.^[4]

While breast cancer is the most well-known cancer associated with HER2 overexpression, this molecular change appears in other cancer types as well. Between 10 and 30 percent of stomach cancers and cancers at the junction where the esophagus meets the stomach show HER2 amplification or overexpression. About 20 percent of stomach cancers overall have this characteristic.^[2]

Colorectal cancer shows HER2 overexpression in approximately 3 to 5 percent of all cases. However, the percentage is higher in colorectal cancers that do not have mutations in other genes like KRAS, NRAS, or BRAF. HER2 overexpression has also been documented in ovarian, endometrial, bladder, lung, colon, and head and neck cancers, though more research is needed to fully understand how it affects tumors in these locations.^[2][3]

In breast cancer specifically, HER2 overexpression is found in about 10 to 20 percent of cases, according to several sources. This represents a substantial number of patients who could potentially benefit from targeted treatments. Interestingly, more than half of breast cancers considered HER2-negative actually have some extra HER2 proteins on their cell surfaces, though not enough to be classified as HER2-positive. These are increasingly called HER2-low or HER2-ultralow cancers.^[1][6]

Risk Factors and Who Is Affected

Because HER2 overexpression results from mutations that occur during a person’s lifetime rather than inherited genetic changes, traditional risk factors like family history do not predict who will develop HER2-positive cancer. The changes happen spontaneously within cells, and scientists are still working to understand what environmental or biological factors might trigger the HER2 gene to amplify.^[5]

HER2 overexpression can occur in any person who develops cancer in one of the affected organ systems. It does not preferentially affect one demographic group over another based on age, gender, or ethnicity. The key factor is whether someone develops cancer and whether that particular cancer happens to have undergone HER2 gene amplification.^[7]

For breast cancer patients, certain tumor characteristics may be more common alongside HER2 overexpression. Research has shown that HER2-positive breast cancers tend to be more aggressive and have a higher tumor grade, meaning the cancer cells look more abnormal under a microscope and tend to grow faster. Before targeted therapies became available, HER2-positive status was associated with worse outcomes compared to other breast cancer subtypes.^[3]

How the Body Is Affected: Pathophysiology

When HER2 proteins are overexpressed on the cell surface, they fundamentally alter the normal mechanisms that regulate cell behavior. Under healthy conditions, HER2 and related receptors form pairs only when stimulated by specific growth factor molecules binding to them from outside the cell. This pairing, called dimerization, activates the receptors and triggers carefully controlled growth signals.^[2]

In HER2 overexpression, the sheer number of receptors crowding the cell surface causes them to spontaneously pair up without waiting for external growth signals. These activated receptor pairs set off a cascade of chemical reactions inside the cell. The receptors add phosphate groups to specific tyrosine amino acids on their internal portions, a process called autophosphorylation. These phosphorylated sites then become docking stations for other signaling proteins.^[2]

Two major signaling pathways become overactive when HER2 is overexpressed. The first is the MAPK/ERK pathway, which drives cell proliferation and tells cells to multiply. The second is the PI3K/AKT/mTOR pathway, which promotes cell survival and prevents cells from dying when they should. Together, these pathways create an environment where cells receive constant signals to grow, divide, and survive, even in the absence of proper growth factors or despite cellular damage that would normally trigger cell death.^[9]

This continuous stimulation gives cells with HER2 overexpression powerful proliferative and anti-death signals. The affected cells become less responsive to the body’s normal control mechanisms. They grow faster, divide more frequently, and resist signals that would ordinarily cause damaged or abnormal cells to die. These characteristics are hallmarks of cancer cells and explain why HER2-positive cancers tend to be particularly aggressive.^[7]

The HER2 signaling network has been described as a complex biological system with multiple layers. At the input layer are the membrane receptors and their binding partners. These feed into signaling pathways that form the processing layer. Finally, at the output layer, these signals influence gene expression and cell behavior. Because HER2 sits at the top of this network, excessive HER2 activity amplifies signals throughout the entire system, leading to profound changes in how cells function.^[7]

Clinical Consequences and Disease Behavior

Cancers with HER2 protein overexpression behave differently from cancers without this molecular characteristic. HER2-positive breast cancers tend to grow faster and spread more quickly than HER2-negative breast cancers. They are more likely to spread to lymph nodes and distant parts of the body, and before targeted therapies became available, they were more likely to recur after initial treatment.^[1]

The aggressive nature of HER2-positive cancers relates directly to the constant growth signals the cancer cells receive. With HER2 receptors continuously activated on the cell surface, the cancer cells divide rapidly and accumulate in large numbers. They also develop the ability to invade surrounding tissues and enter blood vessels or lymphatic channels, which allows them to spread to distant sites in the body, a process called metastasis.^[7]

In bladder cancer and other cancer types, HER2 overexpression is similarly associated with more aggressive tumor behavior and generally poorer outcomes for patients. The molecular mechanisms are similar across cancer types: excessive HER2 signaling drives uncontrolled growth and helps cancer cells survive in conditions where normal cells would die.^[9]

An important clinical observation is that HER2 status can sometimes change over time or with treatment. Some breast cancers that initially test positive for HER2 overexpression may become HER2-negative if the cancer returns after treatment. Similarly, a cancer that was HER2-negative at first diagnosis might become HER2-positive when it recurs. This is why doctors often recommend retesting HER2 status if cancer comes back or spreads to other parts of the body.^[1]

Testing and Diagnosis

Determining whether a cancer has HER2 protein overexpression requires laboratory testing of tissue samples. For breast cancer, testing is done on the primary tumor at the time of diagnosis, along with testing for hormone receptors. For stomach cancer and gastroesophageal junction cancers, HER2 testing is performed on advanced cancers. The test results guide treatment decisions and help doctors predict how the cancer might behave.^[3]

Several laboratory methods can detect HER2 overexpression. The most common are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). These tests work in different ways but both provide information about HER2 status. A third option, next-generation sequencing (NGS), is also sometimes used.^[5]

The IHC test uses special antibodies that stick to HER2 proteins. These antibodies are linked to a colored dye that can be seen under a microscope. A pathologist examines the stained tissue and scores it from 0 to 3+ based on how much HER2 protein is present. A score of 0 or 1+ means the cancer is HER2-negative. A score of 3+ means it is HER2-positive. A score of 2+ is called borderline or equivocal, meaning it is unclear, and usually requires additional testing with FISH.^[1]

The FISH test uses fluorescent probes that attach directly to the HER2 genes in the cell’s chromosomes rather than to the proteins on the cell surface. Under special lighting, these probes glow, allowing laboratory technicians to count how many copies of the HER2 gene are present in each cell. FISH results are reported as positive or negative. FISH positive means there are at least four copies of the HER2 gene on average in the cancer cells, confirming HER2-positive status. FISH negative means gene copy numbers are normal.^[3]

If one test gives unclear results, the other test may be performed to get a more definite answer. Generally, only cancers that score IHC 3+ or FISH positive are considered truly HER2-positive and most likely to respond to targeted treatments designed for this cancer subtype.^[1]

The Development of Targeted Treatments

The discovery of HER2 as a cancer-causing gene opened the door to developing medicines that specifically target this protein. Scientists and pharmaceutical companies have created several types of drugs that work by blocking HER2 signaling or by using HER2 as a way to deliver toxic substances directly to cancer cells. These targeted therapies have dramatically changed the outlook for people with HER2-positive cancers.^[4]

The first breakthrough came with the development of trastuzumab, a monoclonal antibody that binds to HER2 receptors on the cell surface. When trastuzumab attaches to HER2, it prevents the receptor from pairing with other receptors and activating growth signals. It also marks the cell for destruction by the immune system through a process called antibody-dependent cell-mediated cytotoxicity. Clinical trials showed that adding trastuzumab to chemotherapy dramatically improved survival for patients with HER2-positive breast cancer, both in early-stage disease and when cancer had spread.^[8]

Since the approval of trastuzumab, many other HER2-targeted drugs have been developed. These include tyrosine kinase inhibitors (TKIs) that work by blocking the enzyme activity inside the HER2 receptor, preventing it from transmitting growth signals even when it pairs up. Lapatinib was an early example of this class of drugs.^[8]

More recently, antibody-drug conjugates (ADCs) have emerged as powerful new weapons against HER2-positive cancers. These sophisticated medicines combine an antibody that recognizes HER2 with a chemotherapy drug attached to it. The antibody acts like a guided missile, delivering the toxic chemotherapy directly to cancer cells while largely sparing normal cells. ADCs have shown remarkable effectiveness and have expanded treatment options for patients whose cancer has stopped responding to earlier therapies.^[9]

Combination strategies using multiple HER2-targeted drugs together have also shown promise. For example, combining trastuzumab with pertuzumab, another HER2-targeting antibody that binds to a different part of the receptor, has improved outcomes beyond what either drug achieves alone. The development of HER2-targeted therapies continues to evolve, with new drugs and new combinations being tested in clinical trials.^[8]

Impact on Prognosis and Survival

The relationship between HER2 overexpression and patient outcomes has undergone a remarkable transformation. Before targeted therapies existed, HER2-positive breast cancer was associated with worse outcomes than other breast cancer subtypes. The aggressive growth driven by excessive HER2 signaling meant these cancers progressed faster and were more likely to be fatal.^[4]

However, the introduction of HER2-targeted therapies has fundamentally changed this picture. When patients receive appropriate targeted treatment, outcomes for HER2-positive breast cancer have improved dramatically and are now similar to or even better than some other breast cancer subtypes. Some doctors now say that if someone had to choose a type of breast cancer to have, HER2-positive might be preferable because there are so many effective drugs available that specifically target this vulnerability.^[4]

Clinical trials in the adjuvant setting, meaning treatment given after surgery to prevent cancer from returning, have shown that adding trastuzumab to chemotherapy reduces the risk of recurrence by approximately 50 percent compared to chemotherapy alone. This represents one of the most significant improvements in cancer treatment seen in recent decades. Multiple large trials confirmed these benefits, leading to HER2-targeted therapy becoming standard care for patients with HER2-positive early breast cancer.^[7]

For patients with advanced or metastatic HER2-positive cancer, targeted therapies have extended survival and improved quality of life. While metastatic cancer remains incurable, patients on HER2-targeted treatments can experience remissions lasting months or even years, gaining precious time with their families and loved ones. The development of newer drugs, particularly antibody-drug conjugates, has provided options for patients whose cancer develops resistance to earlier treatments.^[8]